PubMed:19759529 / 1808-2080 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":272},"obj":"Sentence"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}

{"project":"LitCoin-entities","denotations":[{"id":"6490","span":{"begin":38,"end":43},"obj":"GeneOrGeneProduct"},{"id":"6491","span":{"begin":55,"end":64},"obj":"ChemicalEntity"},{"id":"6492","span":{"begin":175,"end":187},"obj":"ChemicalEntity"}],"attributes":[{"id":"A44","pred":"db_id","subj":"6490","obj":"NCBIGene:14664"},{"id":"A45","pred":"db_id","subj":"6491","obj":"-1"},{"id":"A46","pred":"db_id","subj":"6492","obj":"MESH:D004298"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T46","span":{"begin":15,"end":23},"obj":"GeneOrGeneProduct"},{"id":"T47","span":{"begin":38,"end":43},"obj":"GeneOrGeneProduct"},{"id":"T48","span":{"begin":44,"end":53},"obj":"GeneOrGeneProduct"},{"id":"T49","span":{"begin":89,"end":93},"obj":"GeneOrGeneProduct"},{"id":"T50","span":{"begin":200,"end":205},"obj":"GeneOrGeneProduct"},{"id":"T51","span":{"begin":206,"end":213},"obj":"GeneOrGeneProduct"},{"id":"T52","span":{"begin":214,"end":218},"obj":"GeneOrGeneProduct"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T25","span":{"begin":38,"end":43},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":44,"end":53},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":89,"end":93},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":206,"end":213},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":214,"end":218},"obj":"GeneOrGeneProduct"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T13","span":{"begin":38,"end":43},"obj":"GeneOrGeneProduct"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T57","span":{"begin":55,"end":64},"obj":"ChemicalEntity"},{"id":"T58","span":{"begin":175,"end":187},"obj":"ChemicalEntity"}],"attributes":[{"id":"A57","pred":"ID:","subj":"T57","obj":"ChemicalEntity"},{"id":"A58","pred":"ID:","subj":"T58","obj":"ChemicalEntity"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T58","span":{"begin":175,"end":187},"obj":"ChemicalEntity"},{"id":"T57","span":{"begin":55,"end":64},"obj":"ChemicalEntity"},{"id":"T21495","span":{"begin":38,"end":43},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A58","pred":"ID:","subj":"T58","obj":"ChemicalEntity"},{"id":"A57","pred":"ID:","subj":"T57","obj":"ChemicalEntity"}],"text":"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs."}